Skip to main content
. 2020 May 7;5(9):e136437. doi: 10.1172/jci.insight.136437

Figure 3. Human pSTAT3–inhibited iTregs produce ample IL-9 and support cutaneous mast cells.

Figure 3

pSTAT3-inhibited or DMSO-treated human iTregs were generated as described. (A) Contour plots and (B) graph (max, min, median) shows the frequency of IL9+, CLA+ CD4+ iTregs after expansion with S3i-201, or DMSO for 5 days from 3 independent experiments. NSG mice received a human skin graft, allogeneic PBMCs, and pSTAT3-inhibited (S3i) or control iTregs. On day +21, the skin grafts were analyzed for mast cell content by tryptase expression using IHC. (C and D) Graph (max, min, median) and representative images show skin grafts from mice treated with pSTAT3-inhibited iTregs demonstrated significantly more mast cells (tryptase = red). n = 3 independent experiments with 9 mice/group. Paired t test (B and C). *P < 0.05 or **P = 0.001–0.01. pSTAT3, STAT3 phosphorylation; iTregs, induced Tregs.